Pharmacologic preconditioning

Innate Tolerance in the CNS: Translational Neuroprotection by Pre- and Post-Conditioning

Volumn , Issue , 2013, Pages 213-224

  Guan, Jian ^a   Keep, Richard F ^a   Hua, Ya ^a   Muraszko, Karin M ^a   Xi, Guohua ^a,b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84940392060     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4419-9695-4_9     Document Type: Chapter

References (51)

1. Ahmed SH, He YY, Nassief A, Xu J, Xu XM, Hsu CY, Furaci FM (2000) Effects of lipopolysaccharide priming on acute ischemic injury. Stroke 31(1):193-199
2. Brambrink AM, Koerner IP, Diehl K, Strobel G, Noppens R, Kempski O (2006) The antibiotic erythromycin induces tolerance against transient global cerebral ischemia in rats (pharmacologic preconditioning). Anesthesiology 104(6):1208-1215
3. Cannon JR, Keep RF, Hua Y, Richardson RJ, Schallert T, Xi G (2005) Thrombin preconditioning provides protection in a 6-hydroxydopamine Parkinson's disease model. Neurosci Lett 373(3):189-194
4. Chen B, Cheng Q, Yang K, Lyden PD (2010) Thrombin mediates severe neurovascular injury during ischemia. Stroke 41(10):2348-2352
5. Chi OZ, Hunter C, Chokshi SK, Weiss HR (2010) Effects of fentanyl pretreatment on regional cerebral blood flow in cerebral ischemia in rats. Pharmacology 85(3):153-157
6. Coughlin SR (2000) Thrombin signalling and protease-activated receptors. Nature 407(6801): 258-264
7. Davies B, Cohen J (2011) Endotoxin removal devices for the treatment of sepsis and septic shock. Lancet Infect Dis 11(1):65-71
8. Dawson TM (2001) Preconditioning-mediated neuroprotection through erythropoietin? Lancet 359(9301):96-97
9. Ehrenreich H, Hasselblatt M, Dembowski C, Cepek L, Lewczuk P, Stiefel M, Rustenbeck HH et al (2002) Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med 8(8):495-505
10. Ehrenreich H, Weissenborn K, Prange H, Schneider D, Weimar C, Wartenberg K, Schellinger PD et al (2009) Recombinant human erythropoietin in the treatment of acute ischemic stroke. Stroke 40(12):e647-e656
11. Eid T, Brines M (2002) Recombinant human erythropoietin for neuroprotection: what is the evidence? Clin Breast Cancer 3(Suppl 3):S109-S115
12. Furuya K, Zhu L, Kawahara N, Abe O, Kirino T (2005) Differences in infarct evolution between lipopolysaccharide-induced tolerant and nontolerant conditions to focal cerebral ischemia. J Neurosurg 103(4):715-723
13. Gidday JM (2010) Pharmacologic preconditioning: translating the promise. Transl Stroke Res 1(1): 19-30
14. Gwaks MS, Li L, Zuo Z (2010) Morphine preconditioning reduces lipopolysaccharide and interferon-gamma-induced mouse microglial cell injury via delta 1 opioid receptor activation. Neuroscience 167(2):256-260
15. Halliwell B (1989) Protection against tissue damage in vivo by desferrioxamine: what is its mechanism of action? Free Radic Biol Med 7(6):645-651
16. Hamill CE, Mannaioni G, Lyuboslavsky P, Sastre AA, Traynelis SF (2009) Protease-activated receptor 1-dependent neuronal damage involves NMDA receptor function. Exp Neurol 217(1): 136-146
17. Hasselblatt M, Ehrenreich H, Sirén AL (2006) The brain erythropoietin system and its potential for therapeutic exploitation in brain disease. J Neurosurg Anesthesiol 18(2):132-138
18. Hu H, Yamashita S, Hua Y, Keep RF, Liu W, Xi G (2010) Thrombin-induced neuronal protection: role of the mitogen activated protein kinase/ribosomal protein S6 kinase pathway. Brain Res 1361:93-101
19. Hua Y, Keep RF, Hoff JT, Xi G (2003) Thrombin preconditioning attenuates brain edema induced by erythrocytes and iron. J Cereb Blood Flow Metab 23(12):1448-1454
20. Hua Y, Nakamura T, Keep RF, Wu J, Schallert T, Hoff JT, Xi G (2006) Long-term effects of experimental intracerebral hemorrhage: the role of iron. J Neurosurg 104(2):305-312
21. Hua Y, Keep RF, Hoff JT, Xi G (2007) Brain injury after intracerebral hemorrhage: the role of thrombin and iron. Stroke 38(2 Suppl):759-762
22. Jiang Y, Wu J, Hua Y, Keep RF, Xiang J, Hoff JT, Xi G (2002) Thrombin-receptor activation and thrombin-induced brain tolerance. J Cereb Blood Flow Metab 22(4):404-410
23. Keberle H (1964) The biochemistry of desferrioxamine and its relation to iron metabolism. Ann N Y Acad Sci 119:758-768
24. Koerner IP, Gatting M, Noppens R, Kempski O, Brambrink AM (2007) Induction of cerebral ischemic tolerance by erythromycin preconditioning reprograms the transcriptional response to ischemia and suppresses inflammation. Anesthesiology 106(3):538-547
25. Kumral A, Gonenc S, Acikgoz O, Sonmez A, Yilmaz O, Gokmen N, Duman N et al (2005) Erythropoietin increases glutathione peroxidase enzyme activity and decreases lipid peroxidation levels in hypoxic-ischemic brain injury in neonatal rats. Biol Neonate 87(1):15-18
26. Lee KR, Colon GP, Betz AL, Keep RF, Kim S, Hoff JT (1996) Edema from intracerebral hemorrhage: the role of thrombin. J Neurosurg 84(1):91-96
27. Lehmann KA (1997) Opioids: overview on action, interaction and toxicity. Support Care Cancer 5(6):439-444
28. Lim YJ, Zhen S, Zuo Z (2004) Morphine preconditions purkinje cells against cell death under in vitro simulated ischemia-reperfusion conditions. Anesthesiology 100(3):562-568
29. Mallard C, Hagberg H (2007) Inflammation-induced preconditioning in the immature brain. Semin Fetal Neonatal Med 12(4):280-286
30. Marti HH, Wenger RH, Rivas LA, Straumann U, Digicaylioglu M, Henn V, Yonekawa Y et al (1996) Erythropoietin gene expression in human, monkey and murine brain. Eur J Neurosci 8(4):666-676
31. Masada T, Xi G, Hua Y, Keep RF (2000) The effects of thrombin preconditioning on focal cerebral ischemia in rats. Brain Res 867(1-2):173-179
32. Mc Kendrick MW (1979) Erythromycin revisited. J Antimicrob Chemother 5(5):495-497
33. Nakamura T, Keep RF, Hua Y, Schallert T, Hoff JT, Xi G (2003) Deferoxamine-induced attenuation of brain edema and neurological deficits in a rat model of intracerebral hemorrhage. Neurosurg Focus 15(4):ECP4
34. Nishino A, Suzuki M, Motohashi O, Umezawa K, Angora H, Yoshimoto T (1993) Thrombin may contribute to the pathophysiology of central nervous system injury. J Neurotrauma 10(2):167-179
35. Palmer C, Roberts RL, Bero C (1994) Deferoxamine posttreatment reduces ischemic train injury in neonatal rats. Stroke 25(5):1039-1045
36. Prass K, Scharff A, Ruscher K, Löwl D, Muselmann C, Victorov I, Kapinya K et al (2003) Hypoxia-induced stroke tolerance in the mouse is mediated by erythropoietin. Stroke 34(8): 1981-1986
37. Riek-Burchardt M, Striggow F, Henrich-Noack P, Reiser G, Reymann KG (2002) Increase of prothrombin-mRNA after global cerebral ischemia in rats, with constant expression of protease nexin-1 and protease-activated receptors. Neurosci Lett 329(2):181-184
38. Ruscher K, Freyer D, Karsch M, Isaev N, Megow D, Sawitzki B, Priller J et al (2002) Erythropoietin is a paracrine mediator of ischemic tolerance in the brain: evidence from an in vitro model. J Neurosci 22(23):10291-10301
39. Selim M (2009) Deferoxamine mesylate: a new hope for intracerebral hemorrhage: from bench to clinical trials. Stroke 40(3 Suppl):s90-s91
40. Semenza GL (2000) HIF-1: mediator of physiological and pathophysiological responses to hypoxia. J Appl Physiol 88(4):1474-1480
41. Siddiq A, Aminova LR, Ratan RR (2008) Prolyl 4-hydroxylase activity-responsive transcription factors: from hydroxylation to gene expression and neuroprotection. Front Biosci 13:2875-2887
42. Sirén AL, Knerlich F, Poser W, Gleiter CH, Brück W, Ehrenreich H (2001) Erythropoietin and erythropoietin receptor in human ischemia/hypoxic brain. Acta Neuropathol 101(3):271-276
43. Stetler RA, Gao Y, Signore AP, Cao G, Chen J (2009) HSP27: mechanisms of cellular protection against neuronal injury. Curr Mol Med 9(7):863-872
44. Straughan JL (1978) Another look at erythromycin. S Afr Med J 54(2):527-530
45. Tuttolomondo A, Di Raimondo D, di Sciacca R, Pinto A, Licata G (2008) Inflammatory cytokines in acute ischemic stroke. Curr Pharm Des 14(33):3574-3589
46. van Nieuw Amerongen GP, van Delft S, Vermeer MA, Collard JG, van Hinsbergh VW (2000) Activation of RhoA by thrombin in endothelial hyperpermiability: role of Rho kinase and protein tyrosine kinases. Circ Res 87(4):335-340
47. Villa P, Bigini P, Mennini T, Agnello D, Laragione T, Cagnotto A, Viviani B et al (2003) Erythropoietin selectively attenuates cytokine production and in fl ammation in cerebral ischemia by targeting neuronal apoptosis. J Exp Med 198(6):971-975
48. Wang H, Ubl JJ, Reiser G (2002) Four subtypes of protease-activated receptors, co-expressed in rat astrocytes, evoke different physiological signaling. Glia 37(1):53-63
49. Xi G, Keep RF, Hua Y, Xiang J, Hoff JT (1999) Attenuation of thrombin-induced brain edema by cerebral thrombin preconditioning. Stroke 30(6):1247-1255
50. Xi G, Hua Y, Keep RF, Hoff JT (2000) Induction of collagen may attenuate brain edema following intracerebral hemorrhage. Acta Neurochir Suppl 76:501-505
51. Zhao P, Huang Y, Zuo Z (2006) Opioid preconditioning induces opioid receptor-dependent delayed neuroprotection against ischemia in rats. J Neuropathol Exp Neurol 65(10):945-952